Rosellini Scientific has been awarded an NIH Small Business Innovation Research (SBIR) grant to develop a new treatment for Overactive Bladder (OAB). The company has launched nUro Inc., which is developing a non-pharmacological therapy that can be delivered at home. Pre-clinical tests are being conducted with Dr. Paul Yoo, Assistant Research Professor at the University of Toronto.
Dallas, TX, December 24, 2014 — Rosellini Scientific announced today that it was awarded an NIH Small Business Innovation Research (SBIR) grant to develop a wireless neuromodulation implant for the treatment of Overactive Bladder (OAB). OAB is a urological condition related to problems with urinary urgency, frequency, and incontinence that affects roughly 16.5% of the adult population in both the United States and Europe. Neurostimulation of the posterior tibial nerve, located in the patient’s lower leg above the ankle, recently emerged as an effective alternative therapy to unsuccessful behavioral modifications, drug treatments, and irreversible surgical approaches. To achieve and sustain clinical benefits of this therapy, recurrent 30 minute sessions will be needed.
To provide patients with a consistent, convenient, and effective therapy, Rosellini Scientific has launched nUro Inc., which is developing a non-pharmacological therapy that can be delivered at home. The nUro Inc. solution is a wireless neurostimulation system comprising a petite, implanted neurostimulator and an unobtrusive external controller, which is only worn during therapy sessions. With this system the patient is able to deliver the optimal therapy at their convenience, away from the physician’s office.
This Phase I SBIR contract, which is being funded through the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), will be executed under the direction of Dr. Austin Duke, VP of Emerging Therapies at Rosellini Scientific, and Dr. Paul Yoo, Assistant Research Professor at the University of Toronto. “We are extremely proud of all that we’ve accomplished to date regarding the development of the nUro Inc. wireless neurostimulator,” said Dr. Duke. “We are equally enthusiastic to partner with the NIH and Dr. Yoo to continue the next stages of development as we strive to bring this system to the patients needing it the most.”
About Rosellini Scientific:
Rosellini Scientific invests both expertise and capital in the development, management, and post-market support of medical technology. The company fosters technology development through collaborations with leading researchers, as well as partnerships with pioneering companies and universities. Rosellini Scientific is creating an active market for translational medicine that connects all stakeholders. Visit http://www.RoselliniScientific.com to learn more.